Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page
- Check4 days agoChange DetectedNew help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment notice states that no participants are being sought. A revision tag Revision: v3.6.0 was added, and the 'Intervention / Treatment' heading was reformatted to 'Intervention/Treatment'.SummaryDifference0.4%

- Check11 days agoChange DetectedThe page revision history shows a new entry Revision: v3.5.5, replacing the previous v3.5.4 entry. This indicates a small metadata/version update rather than any change to the study data or descriptions.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedA new revision tag v3.5.4 was added and the previous tag v3.5.3 was removed. This indicates a revision to the page's history rather than substantive content changes.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page’s footer/site revision version is updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check90 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.